Abstract

BackgroundAlthough feelings of anxiety and depression are common in patients with chronic obstructive pulmonary disease (COPD), little is known about the estimates of their incidence in patients with asthma-COPD overlap (ACO), which has been described and acknowledged as a distinct clinical entity. We aimed to estimate the risk of depression and anxiety among patients with ACO and compare it with the risk among those with COPD alone in the general population.MethodsWe conducted a nationwide population-based retrospective cohort study using the Korean National Sample Cohort database between 1 January, 2002, and 31 December, 2013. Patients who were diagnosed with COPD (International Classification of Diseases, 10th revision [ICD-10] codes J42-J44) at least twice and prescribed COPD medications at least once between 2003 and 2011 were classified into two categories: patients who were diagnosed with asthma (ICD-10 codes J45-J46) more than twice and at least once prescribed asthma medications comprised the ACO group, and the remaining COPD patients comprised the COPD alone group. Patients who had been diagnosed with depression or anxiety within a year before the index date were excluded. We defined the outcome as time to first diagnosis with depression and anxiety. Matched Cox regression models were used to compare the risk of depression and anxiety among patients with ACO and patients with COPD alone after propensity score matching with a 1:1 ratio.ResultsAfter propensity score estimation and matching in a 1:1 ratio, the cohort used in the analysis included 15,644 patients. The risk of depression during the entire study period was higher for patients with ACO than for patients with COPD alone (adjusted hazard ratio, 1.10; 95% confidence interval, 1.03–1.18; P value = 0.0039), with an elevated risk in patients aged 40–64 years (1.21; 1.10–1.34; 0.0001) and in women (1.18; 1.07–1.29; 0.0005). The risk of anxiety was higher for patients with ACO than for patients with COPD alone (1.06; 1.01–1.12; 0.0272), with a higher risk in patients aged 40–64 years (1.08; 1.00–1.17; 0.0392); however, the risk was not significant when stratified by sex.ConclusionsThis population-based study revealed a higher incidence of depression and anxiety in patients with ACO than in patients with COPD alone.

Highlights

  • Feelings of anxiety and depression are common in patients with chronic obstructive pulmonary disease (COPD), little is known about the estimates of their incidence in patients with asthma-COPD overlap (ACO), which has been described and acknowledged as a distinct clinical entity

  • The COPD cohort included patients older than 40 years who had been diagnosed with COPD at least twice as a principal or secondary diagnosis coded according to the International Classification of Disease, tenth revision (ICD-10 codes J42, J43, and J44) and with at least 1 prescription for ≥1 of the following COPD medications: inhaled corticosteroids (ICSs), inhaled long-acting β2-agonists (LABAs), an ICS and a long-acting β2agonists (LABAs) combined in a single inhaler (ICS/LABA), inhaled short-acting β2-agonists (SABAs), inhaled long-acting muscarinic antagonists (LAMAs), short-acting muscarinic antagonists (SAMAs), a SAMA and a SABA combined in a single inhaler (SAMA/ SABA), oral leukotriene antagonists, xanthine derivatives, mast cell stabilizers, and systemic corticosteroids (CSs)

  • After excluding patients who were diagnosed with anxiety or depression within 1 year before the index date, 12,866 patients were included in the initial cohort of ACO and 10,699 patients were included in the initial cohort of COPD alone

Read more

Summary

Introduction

Feelings of anxiety and depression are common in patients with chronic obstructive pulmonary disease (COPD), little is known about the estimates of their incidence in patients with asthma-COPD overlap (ACO), which has been described and acknowledged as a distinct clinical entity. Comorbidities contribute to the overall severity and economic burden of COPD [1] Among such comorbidities, anxiety and depression contribute to a substantial burden of COPD-related morbidity, notably by impairing quality of life and reducing adherence to treatment [2]. ACO can be useful for clinicians in terms of identifying patients with an expected poor outcome through overlapping clinical characteristics of asthma and COPD [10, 11].

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call